Solomon DH, et al. - Researchers evaluated the risks and benefits of low-dose aspirin in RA population when administered for primary cardiovascular prevention. They conducted a cohort study and estimated incidence rates and hazard ratios (HRs) using Cox regression in subjects with RA but no known CV disease in the Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen trial. A similar risk of major NSAID toxicity and major adverse CV events was seen in RA patients using low-dose aspirin with chronic NSAIDs and esomeprazole as patients who did not use it.